Ozempic vs. Wegovy on Medicare Part D in 2026: Formulary Tiers, the $2,000 OOP Cap, and Why Your Coverage Depends on Your Diagnosis
Ozempic vs. Wegovy on Medicare Part D in 2026: Formulary Tiers, the $2,000 OOP Cap, and Why Your Coverage Depends on Your Diagnosis
You've started a GLP-1 medication — or your doctor is recommending one. Now you need to know exactly what Medicare will pay, what you'll pay, and when. The answer is not simple, because it depends on why you're taking the drug, which plan you're on, and what month of the year it is.
Here's what's actually happening with GLP-1s and Medicare in 2026 — with dollar amounts, not generalities.
The Core Problem: Medicare Draws a Sharp Line Between Diabetes and Weight Loss
Medicare Part D has covered GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) for Type 2 diabetes management for years. These drugs sit on most formularies at Tier 3 or Tier 4 (specialty tier).
But Medicare explicitly excludes drugs used primarily for weight loss, which means Wegovy (semaglutide at higher dose) and Zepbound (tirzepatide for weight loss) are not covered under standard Part D — period. This exclusion dates back to a 1990s Medicare statute that predates both the obesity epidemic and the GLP-1 drug class.
A KFF Health News report published this month on GLP-1 medications underscored that these drugs require sustained behavioral engagement — regular movement and mental health support — to be effective long-term. That clinical context matters here too: beneficiaries who need these drugs aren't seeking a shortcut; they have real metabolic and cardiovascular indications. But the Medicare statute doesn't distinguish effort. It distinguishes diagnosis.
The practical result:
| Drug | Indication | Part D Coverage | Monthly List Price |
|---|---|---|---|
| Ozempic (semaglutide 0.5–2mg) | Type 2 Diabetes | ✅ Covered | ~$969 |
| Rybelsus (oral semaglutide) | Type 2 Diabetes | ✅ Covered | ~$935 |
| Mounjaro (tirzepatide) | Type 2 Diabetes | ✅ Covered | ~$1,023 |
| Wegovy (semaglutide 2.4mg) | Weight Loss Only | ❌ Excluded | ~$1,349 |
| Zepbound (tirzepatide) | Weight Loss Only | ❌ Excluded | ~$550–650 with coupon |
| Victoza/Trulicity | Type 2 Diabetes | ✅ Covered (most plans) | ~$800–900 |
If your prescription is for diabetes, you have coverage. If it's for obesity only, you're largely on your own under standard Part D.
What Ozempic Actually Costs You in 2026 — Phase by Phase
The Inflation Reduction Act restructured Part D so that 2025–2026 are genuinely different from prior years. The most important change: the out-of-pocket cap is now $2,000 per year. The old "donut hole" that used to spike your costs mid-year is effectively gone, replaced by a simpler three-phase structure.
Here's how the math works for a beneficiary on a standard Part D plan taking Ozempic at the 1mg dose (~$969/month list price) with no manufacturer discount applied:
2026 Part D Phase Structure
Phase 1 — Deductible: You pay 100% up to $590.
Phase 2 — Initial Coverage: You pay 25% coinsurance; your plan pays 75%. This continues until your out-of-pocket spending reaches $2,000.
Phase 3 — Catastrophic: After $2,000 OOP, you pay $0 for covered drugs for the rest of the year.
Worked Calculation: Ozempic 1mg, 2026 Part D
| Month | What You Pay | Running OOP Total |
|---|---|---|
| January | $590 (deductible) + $95 (25% × $379 remaining) | $685 |
| February | $242 (25% × $969) | $927 |
| March | $242 | $1,169 |
| April | $242 | $1,411 |
| May | $242 | $1,653 |
| June | $242 | $1,895 |
| July | $105 to hit cap, then $0 | $2,000 |
| Aug–Dec | $0 | $2,000 |
Your annual out-of-pocket cost for Ozempic with Part D: $2,000
Without any drug coverage: $969 × 12 = $11,628
The $2,000 OOP cap saves you roughly $9,600 on Ozempic alone in a single year. That's the ACA-era infrastructure (which built the foundation for the IRA's drug pricing reforms) working exactly as intended. The Medicare Rights Center's review of sixteen years of ACA impact, published this week, highlighted how the law's gradual closure of the coverage gap set the stage for the $2,000 cap that beneficiaries now rely on.
This is the kind of phase-by-phase math Toravine can run for your specific drugs, doses, and plan — so you know exactly which month you hit catastrophic coverage.
The Wegovy Problem: $16,000 a Year if You're Paying Out of Pocket
If your doctor prescribed Wegovy for weight management — not as an adjunct to diabetes care — you're facing a different calculation entirely.
No standard Part D coverage. No $2,000 cap applies because the drug isn't a covered benefit.
| Scenario | Annual Cost |
|---|---|
| Wegovy, no coverage | $1,349 × 12 = $16,188 |
| Wegovy, manufacturer savings card (not available to Medicare beneficiaries) | N/A — Medicare rules prohibit this |
| Wegovy, Medicare Advantage extra benefit (rare) | $0–$600/year (plan-specific) |
| Ozempic for T2D with Part D | $2,000 OOP max |
Some Medicare Advantage plans have begun offering supplemental coverage for weight loss drugs as an additional benefit, but as of 2026 this is not universal, not guaranteed to continue year to year, and varies dramatically by plan and geography. If you're relying on an MA plan's weight loss drug benefit, verify it in writing in the plan's Evidence of Coverage document — not the marketing brochure.
Formulary Tier Placement: Not All Covered GLP-1s Cost the Same
Even when a GLP-1 is covered, formulary tier placement determines your actual copay. Two plans can both cover Ozempic and charge you very different amounts before you hit the OOP cap.
Here's a real-world comparison across three hypothetical 2026 Part D plans in a major metro area:
| Plan | Monthly Premium | Ozempic Tier | Deductible | Estimated Annual OOP (Ozempic) |
|---|---|---|---|---|
| Plan A (national PDP) | $38/mo | Tier 4 (25% coinsurance) | $590 | $2,000 (hits cap by July) |
| Plan B (regional PDP) | $12/mo | Tier 3 (20% coinsurance) | $590 | $2,000 (hits cap by August) |
| Plan C (MA-PD) | $0/mo | Tier 5 (33% coinsurance) | $0 | $2,000 (hits cap by June) |
Interesting result: because Ozempic is expensive enough, most beneficiaries on any of these plans hit the $2,000 cap within 6–8 months regardless of tier. The tier placement affects when you hit the cap, not whether you do.
Where tier placement matters more is for lower-cost diabetes drugs — older GLP-1s, metformin, or other adjuncts — where you may never reach the OOP cap and so the coinsurance percentage is what you actually pay all year.
If you're on Mounjaro (tirzepatide for T2D), the math is nearly identical to Ozempic — you'll hit the $2,000 cap around the same time of year. But if your plan hasn't added Mounjaro to its formulary, you may face a prior authorization hurdle or a non-formulary exception process that adds weeks of delay.
Always run the formulary check before January 1. Part D formularies reset every year. A drug that was Tier 3 in 2025 can be Tier 5 in 2026, and a drug that was covered can be removed entirely. If you didn't re-compare during Open Enrollment (October 15 – December 7), it's worth checking now whether your current plan still covers your GLP-1 at the tier you expected.
The MA OEP Window Is Closing March 31 — And It Has a Drug Coverage Catch
If you're enrolled in a Medicare Advantage plan and your plan changed its formulary coverage for GLP-1s at the start of 2026, the Medicare Advantage Open Enrollment Period (MA OEP), which ends March 31, is your one opportunity to switch plans mid-year. As the Medicare Rights Center confirmed this week, this window allows one plan change, effective April 1.
But here's what many beneficiaries don't realize: switching Medicare Advantage plans during MA OEP means your new plan's formulary applies going forward — and your OOP accumulation does not carry over to a new plan. If you've already spent $1,200 toward the $2,000 cap under your current plan, switching resets that counter to zero.
In the Ozempic example above: if you switch in March with $927 already accumulated, you restart the deductible under the new plan. You'd owe another $590 deductible before any coverage kicks in. That's a $590 penalty for switching at the wrong moment — on top of any formulary differences.
The calculus: Is the new plan's coverage of Wegovy (or better Ozempic tier) worth resetting your OOP counter? Run the numbers before switching.
You can model this exact scenario at Toravine — including the mid-year switching cost and the projected savings from a better formulary tier.
What If Your Drug Gets Dropped From Formulary Mid-Year?
This shouldn't happen — plans are generally prohibited from removing covered drugs mid-year except in narrow circumstances (like a drug being recalled). But formulary tier changes mid-year are allowed in some cases.
If your plan drops your GLP-1 or moves it to a non-preferred tier during the year:
- Request a formulary exception — your doctor submits a letter explaining medical necessity
- File for a coverage determination through your plan
- If denied, escalate to an Independent Review Entity (IRE)
These processes take time. If you're in the middle of a diabetes management regimen, a lapse in Ozempic coverage can have real clinical consequences. Having documentation of your medical necessity upfront — especially for newer agents like Mounjaro — shortens this process.
The Long-Term Cost Picture: 10 Years on a GLP-1 for Diabetes
Let's project forward. If you're 65 today, diagnosed with T2D, and your doctor expects you'll need an injectable GLP-1 long-term:
| Scenario | Annual Drug OOP | 10-Year Total Drug OOP | Notes |
|---|---|---|---|
| Original Medicare + Part D | $2,000 | ~$20,000 | Assumes $2,000 cap holds |
| MA-PD with $0 premium | $2,000 | ~$20,000 | Same OOP cap, but plan may change formulary |
| No Part D, no coverage | $11,628 | ~$116,280 | Pre-IRA scenario |
| Wegovy (weight loss), no coverage | $16,188 | ~$161,880 | No OOP cap applies |
The $2,000 cap is genuinely landmark protection for beneficiaries on expensive specialty drugs. The ACA's gradual phase-down of the coverage gap — which the Medicare Rights Center traces through sixteen years of implementation — is what made this ceiling politically and structurally possible.
But the 10-year projection carries two important caveats:
- Formulary status for GLP-1s is not guaranteed. Plans can and do change covered drugs.
- If proposed CMS rule changes discussed in recent Medicare Rights Center commentary reduce plan formulary obligations, specialty drug tier protections could erode.
As we've discussed in prior posts, the choice between Original Medicare and Medicare Advantage isn't just about premiums — it's about which structure gives you the most predictable drug coverage over a decade.
What You Should Do Before April 1
- Check your current plan's formulary for every GLP-1 you take — verify the tier, prior authorization requirements, and quantity limits at medicare.gov/plan-compare
- If you're on Wegovy for weight loss only, ask your plan if any supplemental benefit covers it — and get it in writing in the EOC
- If you're considering switching during MA OEP, calculate how much OOP you've already accumulated and whether resetting makes financial sense
- If you missed Open Enrollment without comparing drug plans, note your current OOP accumulation and plan to re-compare in October
The Part D formulary system is one of the most consequential — and least-reviewed — parts of Medicare. Most beneficiaries set it once and forget it. But drug pricing, tier placement, and formulary inclusion change every single year.
Toravine was built specifically to surface these year-over-year formulary shifts and model what they cost you — across all your medications, not just the expensive one. If you're on a GLP-1 plus metformin plus a statin plus a blood pressure medication, the right plan depends on the combined formulary picture, not any single drug. That's the analysis worth running before your next enrollment window.
Sources
- Sixteen Years of the Affordable Care Act — Medicare Rights Center
- Proposed Rule Could Undermine ACA Coverage — Medicare Rights Center
- The Annual Deadline to Make Certain Medicare Advantage Changes Is Fast Approaching — Medicare Rights Center
- Keep care accessible and affordable for patients — Healthcare Dive
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health — KFF Medicare